Beam Therapeutics (BEAM) Cash from Investing Activities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Cash from Investing Activities data on file, last reported at $25.3 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 120.2% year-over-year to $25.3 million in Q1 2026; TTM through Mar 2026 was $28.9 million, a 74.49% decrease from a year earlier, with the FY2025 full-year figure at -$121.4 million, down 165.64% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $25.3 million, down from $108.4 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for BEAM reached as high as $126.3 million in Q4 2024 and fell as low as -$537.3 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$17.7 million across 5 years, with a median of $24.7 million in 2024.
• Across the five-year window, Cash from Investing Activities plunged 3186.85% in 2023 and soared 341.43% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $113.4 million in 2022, then decreased by 13.52% to $98.1 million in 2023, then gained by 28.73% to $126.3 million in 2024, then slipped by 14.15% to $108.4 million in 2025, then slumped by 76.69% to $25.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $25.3 million in Q1 2026, $108.4 million in Q4 2025, and $65.7 million in Q3 2025.